Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.

Dihydrotestosterone (DHT) worsens heart enlargement, and blocking it may help prevent heart issues.

This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.

This study in rats found that a new hydroxypropyl-β-cyclodextrin formulation of minoxidil reduced the adverse cardiovascular and proliferative effects seen with traditional minoxidil solutions.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

In this study, finasteride increased cardiac damage but reduced mutagenic effects in male rats treated with anabolic steroid ND, suggesting variable organ-specific responses to metabolic inhibition.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This study found that rapidly administered intravenous cimetidine may cause a significant drop in blood pressure in critically ill patients, whereas ranitidine does not appear to have the same effect.

This study observed that urologists are more likely than primary care physicians to prescribe a variety of alpha blockers and newer medications, indicating a broader awareness of treatment options for benign prostate enlargement.

This abstract reviews the role of finasteride and potential dual 5alpha-reductase inhibitors in treating benign prostatic hyperplasia, suggesting that dual inhibitors may offer greater DHT suppression and therapeutic advantages, while emphasizing the need for clinical evaluation.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This study suggests that a biomaterial-based approach using microneedles and ion solutions to deliver SiO3 2− ions may disrupt inflammatory cycles and improve outcomes in inflammatory dilated cardiomyopathy (iDCM).

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

This study evaluated a menthol-based microemulsion for transdermal delivery of finasteride and silodosin, finding that it enhanced skin permeation and flux compared to aqueous solutions, suggesting a promising method for managing benign prostatic hyperplasia.

This study found that dutasteride may help prevent enteric neuronal damage in an animal model of Parkinson's disease, highlighting its potential for drug repurposing to address neuroinflammation.

This study identified several drugs that may be potential candidates for repurposing as anti-hyperhidrosis treatments, based on their association with hypohidrosis or anhidrosis in the FDA Adverse Event Reporting System.

This review discusses the uncommon but potentially serious cutaneous reactions to beta-adrenergic blockers and the uncertain pathogenesis, with no new clinical results reported.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This case study indicates that older patients with NMOSD may show favorable clinical improvements with aggressive treatment, even when the intervention is initiated later in the disease course.

This study established a new reverse-phase high-performance liquid chromatography method to accurately and precisely quantify silodosin and dutasteride in mixtures, meeting International Council of Harmonization validation criteria for stability, sensitivity, and recovery.

This review examines the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia, noting moderate positive effects without complete cure and the need for further research to understand drug mechanisms and pathogenesis.

This study found that finasteride reduced VEGF expression and microvessel density in the renal tissue of diabetic rats, suggesting its potential for treating diabetic microvascular complications.

This study found that finasteride may reduce inappropriate sexual behaviors in geriatric patients with vascular dementia and benign prostate hyperplasia without serious side effects, though some patients required additional medications.

This study suggests that the use of tamsulosin may worsen sleep-disordered breathing in some patients with obstructive sleep apnea being treated with CPAP.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

In this rat model of diabetic neuropathic pain, the study found that testosterone metabolites dihydrotestosterone and 3α-diol may have analgesic effects through different mechanisms.

A new treatment using special microneedles and a nitric oxide-releasing drug could improve hair growth and be more convenient for people with hair loss.